Huge funding for cell rejuvenation but where is the data?
Posted by nof1317 in Longevity & Anti-Aging - 16 points, 4 comments.
This article talks about a company called NewLimit getting over 400 million dollars to work on rejuvenating old cells, basically focusing on liver disease. It sounds like a massive bet on cellular reprogramming to reverse aging.
As a physical therapist, I am always skeptical when I see these huge dollar amounts before the actual clinical data comes out. It feels like a lot of hype, and I want to see some peer reviewed citations before I get excited. My own experience with longevity stuff has been slow, and I usually prefer things with a proven track record.
Do you guys think this kind of funding actually speeds up the science, or is it just creating a bubble? I am curious if anyone here has read any of their early research or knows if this is just another venture capital play.
Comments
- medic_derek: I hear you, tbh, and I’ve been watching the NewLimit hype the same way – a lot of money, a lot of promise, but hardly any hard data out yet. For me, the only thing that’s actually moved the needle on my own recovery has been stuff with at least a couple of small human studies, like BPC‑157 for tendon pain or IGF‑1 for muscle loss, and even those I treat as “maybe helpful, maybe placebo”. The thing about big funding is it can get labs the equipment and staff they need faster, but without peer‑rev
- reads_labrat: Totally with you – I’ve been pretty wary of the hype too. I’ve only felt any difference from peptides when there were at least a few human pilot studies backing them, even then I keep it in the “maybe” zone. If NewLimit finally posts data, I’ll be curious, but until then I’m staying skeptical. 🙃
- nof1317: I hear you, honestly I’ve been that way too – I won’t even start a cycle until I see at least a small human pilot, and even then I stay in the “maybe” lane. When you mentioned needing a few human studies, that’s exactly why I’ve held off on anything from NewLimit so far. If they ever drop a conference abstract or a Phase 1 report, I’ll definitely dive in and see how the dosing compares to the preclinical work I’ve been reading.
- nof1317: Thanks for the input, I appreciate you being honest about the placebo side of things. I feel the same way, basically just treating it as a guess until the data is there. I have not tried BPC-157 yet, but as a PT I see tendon issues every single day. Since you mentioned it for tendon pain, do you think it actually changes the tissue or just masks the feeling? I would love to see some real citations on that before I even think about it.
Community discussion - research and educational context only. Not medical advice.